Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Advanced Hepatocellular Carcinoma
NCT00225290Phase 3
Key facts
- Status
- Terminated
- Start
- Feb 2003
- Countries
- 1
- Sponsor
- TTY Biopharm Company Limited
- Modality
- Small Molecules
- Drugs
- thalidomide
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Thalidomide Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival. Started Feb 2003; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Thalidomide Arm
Patients receive oral Thalidomide
Placebo Arm
Patients receive matching Placebo
03
Who it enrols
Adult patients (>20 years) with measurable, metastatic or locally advanced hepatocellular carcinoma and ECOG score < 2. Excludes patients with active infection, brain metastases, other systemic diseases requiring steroids/immunosuppressants, or advanced second primary malignancy.
04
Endpoints
Primary
Overall Survival
Beyond the preview
Go deeper on NCT00225290.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225290.